Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 2:11:622509.
doi: 10.3389/fimmu.2020.622509. eCollection 2020.

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Affiliations
Review

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Weiqin Jiang et al. Front Immunol. .

Abstract

Tumor-specific CD8+T cells are exposed to persistent antigenic stimulation which induces a dysfunctional state called "exhaustion." Though functioning to limit damage caused by immune response, T cell exhaustion leads to attenuated effector function whereby cytotoxic CD8+T cells fail to control tumor progression in the late stage. This pathway is a dynamic process from activation to "progenitor exhaustion" through to "terminally exhaustion" with distinct properties. With the rapid development of immunotherapy via enhancing T cell function, new studies are dissecting the mechanisms and identifying specific biomarkers of dynamic differentiation during the process of exhaustion. Further, although immune checkpoint inhibitors (ICIs) have achieved great success in clinical practice, most patients still show limited efficacy to ICIs. The expansion and differentiation of progenitor exhausted T cells explained the success of ICIs while the depletion of the progenitor T cell pool and the transient effector function of terminally exhausted T cells accounted for the failure of immune monotherapy in the context of exorbitant tumor burden. Thus, combination strategies are urgent to be utilized based on the reduction of tumor burden or the expansion of the progenitor T cell pool. In this review, we aim to introduce the concept of homeostasis of the activated and exhausted status of CD8+T cells in the tumor immune microenvironment, and present recent findings on dynamic differentiation process during T cell exhaustion and the implications for combination strategies in immune therapy.

Keywords: CD8+ T cell activation; CD8+ T cell exhaustion; differentiation; immunotherapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
T cell differentiation is a dynamic process during which various mechanisms function to determine the bifurcation from effector or memory toward exhaustion. T cell exhaustion has recently been identified as not a fixed state whereby progenitor exhausted T cells give rise to terminally exhausted T cells. While progenitor exhausted T cells exhibit poor cytotoxicity but are long-lived with stem-like properties, terminally exhausted T cells have increased cytotoxicity but are short-lived. The distinct properties of exhausted T cells imply the potential of immunotherapy-based combination strategy in cancer treatment. Tmem, memory T cell; Teff, effector T cell; Tex, exhausted T cell.

References

    1. Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity (2013) 39(1):1–10. 10.1016/j.immuni.2013.07.012 - DOI - PubMed
    1. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 15(8):486–99. 10.1038/nri3862 - DOI - PMC - PubMed
    1. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 11(11):805–12. 10.1038/nrc3153 - DOI - PMC - PubMed
    1. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2015) 21(1):24–33. 10.1016/j.molmed.2014.10.009 - DOI - PMC - PubMed
    1. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 168(4):707–23. 10.1016/j.cell.2017.01.017 - DOI - PMC - PubMed

Publication types